Insider Selling: Natera, Inc. (NASDAQ:NTRA) COO Sells 4,256 Shares of Stock

Natera, Inc. (NASDAQ:NTRAGet Rating) COO Robert Alan Schueren sold 4,256 shares of the firm’s stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $176,879.36. Following the completion of the sale, the chief operating officer now owns 4,226 shares of the company’s stock, valued at approximately $175,632.56. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Robert Alan Schueren also recently made the following trade(s):

  • On Monday, January 9th, Robert Alan Schueren sold 2,244 shares of Natera stock. The shares were sold at an average price of $37.62, for a total transaction of $84,419.28.
  • On Tuesday, January 3rd, Robert Alan Schueren sold 4,856 shares of Natera stock. The shares were sold at an average price of $39.55, for a total transaction of $192,054.80.
  • On Wednesday, December 28th, Robert Alan Schueren sold 1,382 shares of Natera stock. The shares were sold at an average price of $39.84, for a total transaction of $55,058.88.

Natera Stock Down 0.7 %

NTRA stock traded down $0.29 during trading hours on Tuesday, reaching $42.94. 1,481,794 shares of the stock were exchanged, compared to its average volume of 1,579,353. The firm’s 50-day moving average is $39.55 and its 200-day moving average is $44.06. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -7.56 and a beta of 1.28. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.10 and a quick ratio of 2.95. Natera, Inc. has a 12 month low of $26.10 and a 12 month high of $74.82.

Natera (NASDAQ:NTRAGet Rating) last released its earnings results on Tuesday, November 8th. The medical research company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.17. The firm had revenue of $210.64 million during the quarter, compared to analysts’ expectations of $208.31 million. Natera had a negative return on equity of 109.07% and a negative net margin of 70.34%. On average, equities research analysts expect that Natera, Inc. will post -5.64 earnings per share for the current year.

Hedge Funds Weigh In On Natera

A number of large investors have recently modified their holdings of the business. International Assets Investment Management LLC acquired a new position in shares of Natera during the 4th quarter worth about $307,000. Xponance Inc. boosted its stake in shares of Natera by 24.7% during the 4th quarter. Xponance Inc. now owns 11,997 shares of the medical research company’s stock worth $482,000 after buying an additional 2,378 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Natera by 32.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,230 shares of the medical research company’s stock worth $90,000 after buying an additional 551 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Natera by 9.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 6,676 shares of the medical research company’s stock worth $268,000 after buying an additional 600 shares during the last quarter. Finally, Maryland State Retirement & Pension System acquired a new position in shares of Natera during the 4th quarter worth about $308,000. 93.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NTRA. Stephens lowered their price target on shares of Natera to $67.00 in a research report on Wednesday, November 16th. Credit Suisse Group lowered their price target on shares of Natera from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Monday, November 14th. Piper Sandler reiterated an “overweight” rating and set a $70.00 price target on shares of Natera in a research report on Tuesday, January 17th. BTIG Research lowered their price target on shares of Natera from $95.00 to $75.00 in a research report on Wednesday, November 9th. Finally, Robert W. Baird reduced their price objective on shares of Natera from $72.00 to $65.00 in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Stories

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.